Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Alissa R, Segal"'
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract SGLT2 inhibitors (SGLT2i) are glucose‐lowering medications which increase the renal threshold for glucose reabsorption and promote glucosuria. Treatment with these agents raises serum ketone levels, and cases of diabetic ketoacidosis (DKA)
Externí odkaz:
https://doaj.org/article/731b0666b80b4e56a8e791f4f9b9f85d
Publikováno v:
Journal of diabetes and its complications. 35(2)
We studied the use of all hypoglycemic agents in periods before and after introduction of SGLT-2 inhibitors in the USA by repeated cross sectional analysis to initially assess improvement in HbA1c control among patients with type 2 diabetes and hyper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025e92ab7b7f1d2adcc135219cd03b72
https://pubmed.ncbi.nlm.nih.gov/33234402
https://pubmed.ncbi.nlm.nih.gov/33234402
Publikováno v:
Diabetes. 69
Purpose: To evaluate whether low-income pediatric patients with type-1 diabetes living in Massachusetts experience disparities in access to insulin pumps and if there are disparities, what are the root causes. Methods: The first part of this study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6bc87ff6964cf15f5c57997e087e548a
https://doi.org/10.2337/db20-2245-pub
https://doi.org/10.2337/db20-2245-pub
Autor:
Nuha ElSayed, Mohammed AlHarbi, Tareef Alaama, Mikala C. Osani, Glenn Matfin, Alissa R. Segal, Raveendhara R. Bannuru, Robert Gabbay
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67a347c3bb77bb1d938c281083ee3500
https://doi.org/10.2139/ssrn.3685916
https://doi.org/10.2139/ssrn.3685916
Autor:
Andrew S. Narva, Amy Barton Pai, Alissa R. Segal, Jenna M. Norton, Macary Weck Marciniak, Holly Divine, Anthony P. Morreale, Joseph J. Saseen, Kenneth Say
Publikováno v:
Annals of Pharmacotherapy. 53:95-100
Millions of Americans use over-the-counter analgesics on a daily basis, and nearly 100 million nonsteroidal anti-inflammatory drug (NSAID) prescriptions are filled per year. In high-risk patients, these medications can disrupt kidney hemodynamics and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a04a396f23a9c202bd255383a32fa6
https://doi.org/10.1177/1060028018789174
https://doi.org/10.1177/1060028018789174
Autor:
Jiankang Liu, Alissa R. Segal, Larry A. Weinrauch, Eric Wisniewski, George Bayliss, John A. D'Elia
Publikováno v:
Clinical Kidney Journal
Background Cardiovascular complications associated with expensive noninsulin agents for type 2 diabetes are the focus of concern in light of the risk of kidney dysfunction with aging. Head-to-head comparisons are unavailable to guide the choice of ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::911a9b11a2f7ca7853ff8b26d9f8a1cf
https://doi.org/10.1093/ckj/sfx020
https://doi.org/10.1093/ckj/sfx020
Publikováno v:
Diabetes. 68
Aligned educational programs for patient and health care provider (HCP) audiences were launched live and online in 2018 and were on-demand for 6 months. The patient program, “New Long-acting insulins for the Treatment of type 2 diabetes: Patient Pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c8158cffc9c3f470a524f2fa9a0fd5e
https://doi.org/10.2337/db19-657-p
https://doi.org/10.2337/db19-657-p
Publikováno v:
Endocrinology and Metabolism Clinics of North America. 45:845-874
Newer insulin products have advanced the evolution of insulin replacement options to more accurately mimic natural insulin action. There are new, modified, and concentrated insulins; administration devices calibrated for both increased concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0eb2419865f51de4b7568e6a950199d
https://doi.org/10.1016/j.ecl.2016.06.009
https://doi.org/10.1016/j.ecl.2016.06.009
Publikováno v:
Journal of Diabetes and its Complications. 31:1197-1199
Hemoglobin A1C is universally used as a marker for glycemic control and to establish glycemic goals in patients with diabetes. In the older population, experts recommend liberating A1C goals to decrease the risk of hypoglycemia. However, it's not cle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff936c96c638e5bf900c3f8cd0f39b2
https://doi.org/10.1016/j.jdiacomp.2017.02.014
https://doi.org/10.1016/j.jdiacomp.2017.02.014
Publikováno v:
Endocrine and Metabolic Medical Emergencies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::044e096e4f54d0e83dc26722f7236046
https://doi.org/10.1002/9781119374800.ch34
https://doi.org/10.1002/9781119374800.ch34
